DK1763515T3 - 4-Triflourmethoxyphenoxybenzen-4'-sulfonsyrer, fremgangsmåde til deres fremstilling og anvendelse i lægemidler - Google Patents

4-Triflourmethoxyphenoxybenzen-4'-sulfonsyrer, fremgangsmåde til deres fremstilling og anvendelse i lægemidler

Info

Publication number
DK1763515T3
DK1763515T3 DK05750284T DK05750284T DK1763515T3 DK 1763515 T3 DK1763515 T3 DK 1763515T3 DK 05750284 T DK05750284 T DK 05750284T DK 05750284 T DK05750284 T DK 05750284T DK 1763515 T3 DK1763515 T3 DK 1763515T3
Authority
DK
Denmark
Prior art keywords
triflourmethoxyphenoxybenzene
pharmaceuticals
preparation
sulfonic acids
sulfonic
Prior art date
Application number
DK05750284T
Other languages
English (en)
Inventor
Manfred Schudok
Armin Hofmeister
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK1763515T3 publication Critical patent/DK1763515T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK05750284T 2004-06-30 2005-06-15 4-Triflourmethoxyphenoxybenzen-4'-sulfonsyrer, fremgangsmåde til deres fremstilling og anvendelse i lægemidler DK1763515T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004031620A DE102004031620A1 (de) 2004-06-30 2004-06-30 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln
PCT/EP2005/006416 WO2006002764A1 (de) 2004-06-30 2005-06-15 4-trifluormethoxyphenoxybenzol-4'-sulfonsäuren, verfahren zu ihrer herstellung und verwendung in arzneimitteln

Publications (1)

Publication Number Publication Date
DK1763515T3 true DK1763515T3 (da) 2008-06-16

Family

ID=34970397

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05750284T DK1763515T3 (da) 2004-06-30 2005-06-15 4-Triflourmethoxyphenoxybenzen-4'-sulfonsyrer, fremgangsmåde til deres fremstilling og anvendelse i lægemidler

Country Status (21)

Country Link
US (2) US20070155778A1 (da)
EP (1) EP1763515B1 (da)
JP (1) JP4871273B2 (da)
KR (1) KR20070026662A (da)
CN (1) CN101035764A (da)
AR (1) AR049557A1 (da)
AT (1) ATE388940T1 (da)
AU (1) AU2005259634A1 (da)
BR (1) BRPI0512656A (da)
CA (1) CA2572126A1 (da)
DE (2) DE102004031620A1 (da)
DK (1) DK1763515T3 (da)
ES (1) ES2299039T3 (da)
IL (1) IL179975A0 (da)
MX (1) MXPA06014189A (da)
MY (1) MY139236A (da)
PE (1) PE20060478A1 (da)
PT (1) PT1763515E (da)
TW (1) TW200612943A (da)
UY (1) UY28994A1 (da)
WO (1) WO2006002764A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10344936A1 (de) * 2003-09-27 2005-04-21 Aventis Pharma Gmbh Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen
DE102005002500A1 (de) 2005-01-19 2006-07-27 Sanofi-Aventis Deutschland Gmbh Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen
CN101680157B (zh) 2007-05-31 2012-03-28 皇家飞利浦电子股份有限公司 用于熨烫系统的固定设备

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9611479B1 (pt) * 1995-11-13 2009-01-13 Ácidos alfa-iminoidroxÂmicos e carboxÍlicos n-substituÍdos cÍclicos e heterocÍclicos.
ES2201318T3 (es) * 1996-08-28 2004-03-16 THE PROCTER & GAMBLE COMPANY Inhibidores de metaloproteasas de aminas ciclicas substituidas.
WO1998050348A1 (en) * 1997-05-09 1998-11-12 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6294573B1 (en) * 1997-08-06 2001-09-25 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
BR9814643A (pt) * 1997-11-14 2000-10-03 Searle & Co Inibidor de metaloprotease de ácido sulfona hidroxâmico aromático
US20010039287A1 (en) * 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6750228B1 (en) * 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
DE10344936A1 (de) * 2003-09-27 2005-04-21 Aventis Pharma Gmbh Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen
DE102004031850A1 (de) * 2004-06-30 2006-01-26 Sanofi-Aventis Deutschland Gmbh Substituirte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament

Also Published As

Publication number Publication date
MY139236A (en) 2009-09-30
ES2299039T3 (es) 2008-05-16
DE102004031620A1 (de) 2006-02-02
PT1763515E (pt) 2008-04-07
JP2008504316A (ja) 2008-02-14
US20070155778A1 (en) 2007-07-05
UY28994A1 (es) 2006-01-31
EP1763515B1 (de) 2008-03-12
AR049557A1 (es) 2006-08-16
KR20070026662A (ko) 2007-03-08
MXPA06014189A (es) 2007-03-12
PE20060478A1 (es) 2006-06-22
BRPI0512656A (pt) 2008-04-01
DE502005003219D1 (de) 2008-04-24
AU2005259634A1 (en) 2006-01-12
ATE388940T1 (de) 2008-03-15
IL179975A0 (en) 2007-05-15
TW200612943A (en) 2006-05-01
WO2006002764A1 (de) 2006-01-12
CA2572126A1 (en) 2006-01-12
CN101035764A (zh) 2007-09-12
JP4871273B2 (ja) 2012-02-08
US20100099663A1 (en) 2010-04-22
EP1763515A1 (de) 2007-03-21

Similar Documents

Publication Publication Date Title
NO2017003I1 (no) Kobicistat eller farmasøytisk akseptabelt salt derav og tenofovir alafenamid eller farmasøytisk akseptabelt salt derav, spesielt tenofovir alafenamidfumarat
DK3401327T3 (da) Genprodukter med forskellig ekspression i tumorer og anvendelser deraf
DK1687049T3 (da) Sprøjter, sprøjtegrænseflader og sprøjtestempler til anvendelse med medicinske injektorer
NO20053593D0 (no) Arylalkylkarbamat-derivater, fremgangsmate og anvendelse derav i terapi
DK1973429T3 (da) Proteinhydrolysater og fremgangsmåde til fremstilling
AT500356A3 (de) Montagevorrichtung zum setzen von einzelnen gegenständen in eine aufnahme
NO20054529D0 (no) Pulver med forbedrede egenskaper, fremgangsmate til dets fremstilling og anvendelse i en fremgangsmate
DE112005003865A5 (de) Grafikintegration in eine Prozesskonfigurations- und Steuerumgebung
NO20054905D0 (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
ZA200700456B (en) Nucleic acid molecules and their use in plant male sterility
DK2029799T3 (da) Termostabile proteiner og fremgangsmåder til fremstilling og anvendelse heraf
DK1708994T3 (da) Aryloxyalkylcarbamatderivater, fremstilling og anvendelse herfra inden for terapi
DK1768833T3 (da) Formlegeme, fremgangsmåde til dets fremstilling samt dets anvendelse
NO20053809D0 (no) Diarylmetylindenpiperidinderivater,fremgangsmate for fremstilling derav, og anvendelse derav
DK1718340T3 (da) Nye effektorkonjugater, fremgangsmåde til deres fremstilling og deres farmaceutiske anvendelse
DK1773829T3 (da) Aminotropanderivater, fremstilling og terapeutiske anvendelser heraf
DK1848440T3 (da) Farmaceutisk sammensætning og fremgangsmåde til regenerering af myofibre i behandlingen af muskelskader
IL184076A0 (en) Membrane card and method for the production and use thereof
DK1791872T3 (da) Biotinylerede hexadecasaccharider, farmaceutiske præparater og anvendelse heraf
DK1531675T3 (da) Midler, som indeholder carboxylsyre, og deres anvendelse i plantedyrkning
DK1763515T3 (da) 4-Triflourmethoxyphenoxybenzen-4'-sulfonsyrer, fremgangsmåde til deres fremstilling og anvendelse i lægemidler
GB2435182B (en) Improvements in and relating to the DNA consideration process
DK1906921T3 (da) Klar farmaceutisk, vandig mikroemulsion omfattende propofol og fremgangsmåde til fremstilling
NO20053805D0 (no) Diarylmetylindenpiperidinderivater, framgangsmate for fremstilling derav, og anvendelse derav
PL376122A1 (pl) Sposób wytwarzania rekombinowanej szczepionki przeciwko krwotocznej chorobie królików, szczepionka oraz zastosowanie antygenu rekombinowanego białka do wytwarzania szczepionki